{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-019462","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.508338+00:00","generated_at":"2026-05-25T17:14:39.141942+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ocular Therapeutix reports FY2024 revenue $63.7M, net loss $(193.5)M; updates AXPAXLI registrational program","bullets":["Q4 2024 revenue $17.1M (+15.4% YoY); FY2024 revenue $63.7M (+9.0% YoY). Net loss $(193.5)M for FY2024 vs $(80.7)M in FY2023.","Cash balance $392.1M as of Dec 31, 2024; expected to fund operations into 2028; no plans to raise additional capital in 2025.","SOL-1 Phase 3 wet AMD trial amended to include re-dosing at Weeks 52 and 76; Week 36 primary endpoint data expected in 1Q 2026.","SOL-R trial size reduced from 825 to 555 subjects due to re-dosing inclusion in SOL-1; non-inferiority margin -4.5 letters BCVA vs aflibercept.","FDA feedback on AXPAXLI clinical trial design for NPDR and DME anticipated in 1H 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-019462","json":"https://secwatch.observer/filing/0001104659-25-019462.json","markdown":"https://secwatch.observer/filing/0001104659-25-019462.md","text":"https://secwatch.observer/filing/0001104659-25-019462.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465925019462/0001104659-25-019462-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465925019462/tm258051d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T17:14:39.141942+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}